8:00 am Check In & Morning Refreshments
8:25 am Chair’s Opening Remarks
Mastering Suprachoroidal Delivery to Increase Distribution & Durability
8:30 am Expanding the Potential of the Suprachoroidal Space in Retinal Therapy
Synopsis
- Evaluating the durability of delivering drugs suprachoroidal to the macula
- Enhancing drug formulation for successful suprachoroidal delivery
- Updating on phase 3 clinical trial developments
9:00 am Considering Non-Invasive Administration of Medications for Retinal Diseases : a Mechanism of Action Perspective
Synopsis
- Understanding the process for delivering drugs to the retina
- Delving into mechanism of action and delivery constraints – the dose and the metabolic variables
- Clarifying preclinical and clinical endpoints – from diverging to converging variables
9:30 am Morning Break
Comparing of Existing Ophthalmic Models Approaches to Supercharge Development
10:30 am Utilizing Preclinical & Computational Models for Predicting Human Ophthalmic Drug Behavior
Synopsis
- Comparing existing rodent, pig, and rabbit models
- Troubleshooting species differences with ocular models to optimize delivery translation
- Addressing the gaps in the current models and applying computational methods for predicting PK/PD
11:00 am Roundtable Discussion: Finding the Ideal Combination of Formulation & Device for Optimal Ocular Delivery
Synopsis
A more practical and highly interactive breakout roundtable session where attendees can crowd-source solutions and
share opinions on pre-assigned topic areas:
- Topical – How can topical treatments duration and penetration be extended?
- Injection – Strategies for optimizing with intravitreal, subretinal, and suprachoroidal injections
- Implant – Key design consideration for intraocular implants to ensure sustained drug release
Moderator Feedback & Audience Debate
Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the
roundtable discussions, they will present back to the entire delegation and open wider audience debate.
12:00 pm Lunch
Delivery Effective Cell & Gene Therapies to the Eye to Halt Vision Loss
1:00 pm Optimizing Current Suprachoroidal & Subretinal Delivery of AAV Gene Therapies
Synopsis
Reviewing the future landscape and the ideal delivery mechanisms to the suprachoroidal and subretinal spaces
1:30 pm Enhancing Cell & Gene Therapies With Advanced Hydrogel Platforms
Synopsis
- Characterizing how hydrogel platforms impact localization and phenotype of injected cells
- Engineering formulations to improve cell viability
- Detailing the potential for tissue regeneration
2:00 pm Exploring Disease Indication & Endpoint Selection for Ophthalmic Gene Therapy Trials to Unlock Optimal Results
Synopsis
- Showcasing how to replicate LUXTERNA results in subsequent RPE65 gene therapies
- Identifying the ideal volume and best vehicle
- Evaluating promotor usage, injection point and AAV virus formulation
2:30 pm Afternoon Break
Innovations with Topical & Oral Medications & the Path to Regulatory Success
3:30 pm Considering Systemic Administration of PPARalpha Agonist for the Treatment of Diabetic Retinopathy & AMD
Synopsis
- Understanding PPARa as a drug target for diabetic retinopathy
- Exploring novel non-fibrate PPARalpha agonists with higher potency and selectivity for PPARalpha agonism
- Demonstrating the effects on retinal degeneration, inflammation and neovascularization in diabetic and AMD animal models